Stress CMR-inducible MI and LGE may predict MACE in HFpEF patients without CAD: Study Medha29 Dec 2021 3:30 AM GMTFrance: A recent study found that stress cardiovascular magnetic resonance (CMR)-inducible myocardial ischemia and late gadolinium enhancement (LGE)...
Treatment with DPP-4i versus sulphonylureas yield similar MACE risk in type 2 diabetics: Study Medha20 Dec 2021 4:15 AM GMTUK: Type 2 diabetes (T2D) patients treated with DPP-4 inhibitors versus sulphonylureas as add-on to metformin has a similar risk of cardiovascular...
Time to Rethink about routine oral Anti-platelet therapy before PCI for Non-ST-Elevated ACS? MD Bureau24 Nov 2021 3:30 AM GMTThe timing of oral P2Y12 inhibitor administration in patients with non-ST elevation acute coronary syndromes (NSTEACS) has been a matter of...
Type 2 diabetes patients with polyvascular disease at increased risk of MACE: EXSCEL trial Medha4 Nov 2021 4:15 AM GMTUSA: The risk of MACE and mortality increases incrementally with each additional diseased arterial bed in patients with type 2 diabetes versus those...
LDL-C level reduction <25 mg/dL with alirocumab not tied to MACE reduction: Circulation Medha29 Jan 2021 3:57 PM GMTUSA: Acute coronary syndrome (ACS) patients treated with alirocumab who achieved LDL-C levels <25 mg/dL versus 25–50 mg/d did not show any...
Semaglutide reduces major adverse CV event risk in Diabetics with raised triglycerides MD Bureau1 Jan 2021 11:45 AM GMTA posthoc analysis on SUSTAIN 6 and PIONEER 6 trial showed semaglutide was associated with consistent reduction in major Adverse cardiovascular event...
Metformin significantly lowers death risk due to cardiac and other causes: Study Medha14 Dec 2020 7:15 AM GMTItaly: Compared to other anti-hyperglycaemic drugs or placebo, the use of metfomin significantly lowers the mortality risk and MACE risk in patients...
High blood sugar levels increase CV risk in elderly diabetics: Study Medha22 July 2020 11:12 AM GMTSpain: HbA1c>7%, a measure of average blood sugar may increase the risk of major adverse cardiovascular events (MACE) in diabetes patients...
Does ticagrelor lower the risk of MACE in patients of ACS undergoing PCI? Dr. K B Aarthi7 March 2020 5:00 AM GMTOne year after PCI, patients taking ticagrelor had similar rates of MACE and faced greater safety risks.
